InVivo Therapeutics has received investigational device exemption approval from the FDA to evaluate the use of its biopolymer scaffold in treating patients with acute spinal cord injuries. The study will take place over 15 months, and the company hopes to submit to the FDA the details of the trial by the end of next year.
InVivo gets FDA OK to test bioscaffold in acute SCI patients
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management